Calgary, Alberta (ots/PRNewswire) - - Canadian Biotechnology Company Takes Next Significant Step Towards Advancing its Product to the Clinic - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical products, today ...
Aachen, Germany (ots) - In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Versatis®, a novel 5 % lidocaine medicated plaster, for the treatment of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN), developed by the German drug company Grünenthal. Following this national approval of Versatis® and its national launch on January, ...
Alderley Park, England (ots/PRNewswire) - - For Non-US Healthcare Press Only AstraZeneca today announced RECENTIN(TM) as the global trademark for AZD2171, its oral, highly potent and selective vascular endothelial growth factor (VEGF) signalling inhibitor. AZD2171 is currently in Phase II/III development for advanced non-small cell lung cancer (NSCLC) and ...
Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company Shortens Clinical Timelines by Eliminating Duplicative Insulin Trials TSX symbol: SBS SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical ...
New York (ots/PRNewswire) - Xenomics, Inc. (the "Company") (OTC Bulletin Board: XNOM; FWB: XE7), source of next-generation medical DNA technologies, announced today the closing of a private placement totaling US$1.0 million, whose proceeds will help to fund the Company's efforts to develop advanced medical diagnostic tests for a range of diseases and genetic conditions, and to fund preparations toward product ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - - Record Production Capabilities Strengthen sanofi pasteur's Global Leadership in the Fight Against Seasonal Influenza and Place the Company at the Forefront of Pandemic Readiness sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY; EURONEXT: SAN), announced that it ...
Basel, Switzerland (ots/PRNewswire) - Today's positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) of Tibotec's boosted protease inhibitor darunavir is good news for HIV treatment-experienced patients facing drug resistance. Studies have shown that darunavir, when used in ...
Pompey, France (ots/PRNewswire) - Solvay Pharmaceuticals and Novasep have signed a five-year strategic manufacturing alliance which includes the exclusive synthesis of two active pharmaceutical ingredients for Solvay Pharmaceuticals. Solvay and Novasep have recently set a strategic manufacturing alliance defining Novasep as a preferred partner for the ...
Lugano (ots) - HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced the successful completion of two phase 3 trials of Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV). Both clinical trials successfully met the primary ...
Amsterdam, The Netherlands (ots/PRNewswire) - - In Germany, 80 Million Patient Cards Will be Renewed Over the Next 5 Years Gemalto (Euronext NL0000400653 GTO), a world leader in digital security, today announces it is taking part in Germany's first healthcare pilot program based on highly secure microprocessor cards. The Gemalto product is fully compliant ...
Basel, Switzerland (ots/PRNewswire) - - Avastin is First Medicine to Extend Survival Beyond One Year in Patients With Previously Untreated Non-Small Cell Lung Cancer Avastin is the first medicine proven to help previously untreated patients suffering from the most common form of lung cancer to live longer than a year, according to a landmark US study ...
Orlando, Florida (ots/PRNewswire) - - The PREVAIL Study Showed That in Acute Ischemic Stroke Patients Treated With Clexane(R) / Lovenox(R), the Risk of Having a VTE was Lowered by a Significant 43% With no Significant Increase in Clinically Important Bleedings When Compared to UFH Sanofi-aventis announced ...
London (ots/PRNewswire) - - Out of the Shadow to Premiere on Psychiatry 24 x 7 Website - Award-Winning Film Offers Hope & Healing to Millions of Families Worldwide Out of the Shadow, Susan Smiley's award-winning documentary film, which offers a searing and captivating portrait of her mother Millie's lifelong struggle with schizophrenia and its shattering impact on her family, is now available to view ...
Paris (ots/PRNewswire) - - New Data Presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) For Non-US Journalists Only New data presented today showed that a substantial number of patients with chronic-phase chronic myelogenous leukaemia (CML) resistant to ...
Basel, Switzerland (ots/PRNewswire) - - Roche to Approach World-Wide Regulatory Authorities for a New File Submission Roche announced today that a large, international Phase III study (NO16967) of 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression-free survival. Study results showed that the chemotherapy ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today that the Company has enrolled its first patient in a pivotal Phase III European/Canadian clinical trial for the treatment of moderate to severe psoriasis with its lead immunosuppressive drug, ISA247. The Phase III European/Canadian psoriasis trial (ESSENCE trial) will be performed at ...
Cape Town, South Africa (ots/PRNewswire) - - First Rimonabant Trial with HbA1c as a Primary Endpoint Sanofi-aventis announced today that new data on rimonabant, its first-in-class cannabinoid type 1 (CB1) receptor blocker, showed that patients with type 2 diabetes not currently treated with anti-diabetic ...
Vancouver, Canada (ots/PRNewswire) - Perceptronix Medical Inc. ("Perceptronix") announced today that it has opened its first sputum induction facility at MDS Metro Laboratory Services' Victoria Drive Patient Service Centre in Vancouver. This facility will be the first centre to offer sputum induction for Perceptronix's ClearSign(TM) Sputum Test ("ClearSign(TM)"). ClearSign(TM) is a simple, non-invasive, early ...
Paris (ots/PRNewswire) - - Photographers From Across Europe Invited to Participate in Contest to Fight Stigma and Discrimination of HIV/AIDS Patients. Bristol-Myers Squibb announced today - World AIDS Day - the launch of the fourth edition of the One Vision European photography competition, an initiative that is literally helping to change the image of HIV and AIDS across Europe. "People are living longer ...
New York (ots/PRNewswire) - - Broad Access Program for Patients with Limited Available Treatment Options Pfizer announced today that it plans to establish a multi-national Expanded Access Program (EAP) to make the investigational CCR5 antagonist maraviroc, currently in ongoing phase 3 clinical ...
Edmonton, Canada, November 28 (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) today announced that its lead immunosuppressive drug, ISA247 is positioned to enter Phase II/ III human clinical trials in uveitis by its partner Lux Biosciences, following interactions with the Food and Drug Administration and ...
Pain Management Research Institute
Sydney, Australia, November 28 (ots/PRNewswire) - - Results Offer Hope to Patients With Excruciating Chronic Pain Findings from a new study published today in the journal Neurology demonstrate that the oral medication pregabalin is significantly effective in relieving central neuropathic (nerve) pain and improves pain-related sleep disturbance and anxiety in patients with spinal cord injury. Conducted by ...
Stafford, England, November 22 (ots/PRNewswire) - Medify Solutions Limited (OTC - MDFY), today announced that due to the achievement of major performance milestones and the positive circumstances created by the significant NHS developments, the company is issuing a 1 for 4 (25%) share dividend. This is also in recognition by the board that the activities announced to shareholders in June 2006 relating to ...
Paris, November 22 (ots/PRNewswire) - - New Hope for CML and Ph+ ALL Patients who Face Resistance or Intolerance to Current Therapies For Non-US Journalists Only Today, the European Commission approved SPRYCEL(TM) (dasatinib, formerly known as BMS-354825) for the treatment of adults with chronic, ...
Edmonton, Alberta, November 21 (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) today announced the Company has received a Notice of Allowance from the United States Patent and Trademark Office based on U.S. Patent Application Serial No. 10/845,747 for TAFA93, including both composition of matter and methods of use claims. This is the first patent to be issued in ...
Swiftwater, Pennsylvania. and Lyon, France, November 20 (ots/PRNewswire) - - New Pre-Pandemic Vaccine Will Provide Additional Level of Preparedness sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY; EURONEXT: SAN) has signed a contract with the Office of Public Health and ...
Shire Pharmaceuticals Group Plc
Basingstoke, England and San Diego, California, November 20 (ots/PRNewswire) - - Further Data Support the Contribution of FOSRENOL(R) (Lanthanum Carbonate) to the Overall Renal Health of the ESRD Patient While Reducing Mean Phosphate Levels to Within Guideline Targets New data presented on Friday 17th ...
Alliance for Better Bone Health
Paris, November 17 (ots/PRNewswire) - - Actonel Almost Halves the Risk of Breaking a Hip When Compared to Alendronate in the First Year of Treatment - For Non-US Journalists Only Data published today from a retrospective study of over 33,000 postmenopausal women showed that among patients newly ...
Macclesfield, England, November 17 (ots/PRNewswire) - FOR INTERNATIONAL JOURNALISTS - NOT FOR US MEDIA - Data Published in the Lancet Oncology Report That Patients are More Likely to Live Cancer Free for Longer if Tamoxifen is Replaced With ARIMIDEXT(TM) According to data published today in the Lancet ...
Edmonton, Canada, November 16 (ots/PRNewswire) - - Transplant Data Presented at the American Society of Nephrology Conference Isotechnika Inc. today announced results from initial data for its Phase IIb kidney transplant trial of the Company's lead immunosuppressive drug, ISA247. To date, 133 patients have been enrolled in the trial. Based on an early ...